Net Loss Per Common Share |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loss per common share: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net Loss Per Common Share |
8. NET LOss per COMMON share
The following table reconciles the weighted-average shares outstanding for basic and diluted net loss per share for the years ended December 31, 2016 and 2015:
For the years ended December 31, 2016 and 2015, the 294,998 and 264,000 equity-based restricted stock awards, respectively, which are unvested, have been excluded from the above calculation as they were anti-dilutive. The net loss per share-diluted also excludes both the 248,625 and 553,473 of contingently issued shares at December 31, 2016 and 2015, respectively, and the 200,000 warrants granted to Opus, as the effect would be anti-dilutive. |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The entire disclosure for earnings per share. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|